In the last trading session, 5.67 million Tenax Therapeutics Inc (NASDAQ:TENX) shares changed hands as the company’s beta touched 2.64. With the company’s per share price at $0.38 changed hands at -$0.04 or -9.21% during last session, the market valuation stood at $9.10M. TENX’s last price was a discount, traded about -1031.58% off its 52-week high of $4.30. The share price had its 52-week low at $0.15, which suggests the last value was 60.53% up since then. When we look at Tenax Therapeutics Inc’s average trading volume, we note the 10-day average is 41.65 million shares, with the 3-month average coming to 6.79 million.

Analysts gave the Tenax Therapeutics Inc (TENX) stock a consensus recommendation rating of a Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended TENX as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Tenax Therapeutics Inc’s EPS for the current quarter is expected to be -$0.09.

Tenax Therapeutics Inc (NASDAQ:TENX) trade information

Instantly TENX was in red as seen at the end of in last trading. With action 144.42%, the performance over the past five days has been green. The drop to weekly highs of 0.7650 on Friday, 11/17/23 subtracted -9.21% to the stock’s daily price. The company’s shares are showing year-to-date downside of -82.89%, with the 5-day performance at 144.42% in the green. However, in the 30-day time frame, Tenax Therapeutics Inc (NASDAQ:TENX) is 30.14% up. Looking at the short shares, we see there were 18100.0 shares sold at short interest cover period of 0.04 days.

The consensus price target for the stock as assigned by Wall Street analysts is $5.50, meaning bulls need an upside of 93.09% from its current market value. According to analyst projections, TENX’s forecast low is $5.00 with $6.00 as the target high. To hit the forecast high, the stock’s price needs a -1478.95% plunge from its current level, while the stock would need to soar -1215.79% for it to hit the projected low.

Tenax Therapeutics Inc (TENX) estimates and forecasts

Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for Tenax Therapeutics Inc will rise 95.90%, while the growth in revenue is estimated to hit 94.20% for the next quarter.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 43.05%. The 2023 estimates are for Tenax Therapeutics Inc earnings to increase by 95.46%.

TENX Dividends

Tenax Therapeutics Inc is expected to release its next quarterly earnings report on November 13.

Tenax Therapeutics Inc (NASDAQ:TENX)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 2.55% of Tenax Therapeutics Inc shares while 3.20% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 3.28%. There are 3.20% institutions holding the Tenax Therapeutics Inc stock share, with Corient Private Wealth LLC the top institutional holder. As of Sep 29, 2023, the company held 0.80% of the shares, roughly 0.19 million TENX shares worth $73003.0.

Geode Capital Management, LLC holds the second largest percentage of outstanding shares, with 0.50% or 0.12 million shares worth $45366.0 as of Sep 29, 2023.

Among Mutual Funds, the top two as of Jun 29, 2023 were Vanguard Extended Market Index Fund and Fidelity NASDAQ Composite Index Fund. With 8691.0 shares estimated at $3313.0 under it, the former controlled 0.04% of total outstanding shares. On the other hand, Fidelity NASDAQ Composite Index Fund held about 0.01% of the shares, roughly 1521.0 shares worth around $579.0.